$5.00
0.60% yesterday
Nasdaq, Aug 27, 10:00 pm CET
ISIN
US02155X1063
Symbol
ATHE

Alterity Therapeutics Ltd. Sponsored ADR Stock price

$5.00
-0.58 10.39% 1M
+1.13 29.20% 6M
+1.69 51.06% YTD
+3.45 222.58% 1Y
-0.85 14.56% 3Y
-20.00 80.00% 5Y
-48.41 90.64% 10Y
-92.80 94.89% 20Y
Nasdaq, Closing price Wed, Aug 27 2025
-0.03 0.60%
ISIN
US02155X1063
Symbol
ATHE
Industry

Key metrics

Basic
Market capitalization
$77.8m
Enterprise Value
$75.0m
Net debt
positive
Cash
$3.0m
Shares outstanding
5.3b
Valuation (TTM | estimate)
P/E
- | negative
P/S
457.9 | 63.8
EV/Sales
441.0 | 61.2
EV/FCF
-
P/B
15.4
Financial Health
Equity Ratio
-
Return on Equity
-
ROCE
-254.7%
ROIC
-596.1%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$170.0k | $1.1m
EBITDA
$-12.9m | -
EBIT
$-13.0m | -
Net Income
$-12.9m | $-4.4b
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
112.5% | 556.5%
EBITDA
-39.9% | -
EBIT
-39.7% | -
Net Income
-61.1% | -34,998.0%
Free Cash Flow
-
Margin (TTM | estimate)
Gross
-
EBITDA
-7,575.0% | -
EBIT
-7,630.9%
Net
-7,573.5% | -390,921.0%
Free Cash Flow
-
More
EPS
$0.0
FCF per Share
-
Short interest
1.0%
Employees
10
Rev per Employee
$20.0k
Show more

Is Alterity Therapeutics Ltd. Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Financial data from Alterity Therapeutics Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
0.17 0.17
113% 113%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 3.72 3.72
31% 31%
2,188%
- Research and Development Expense 12 12
53% 53%
6,882%
-13 -13
40% 40%
-7,571%
- Depreciation and Amortization 0.10 0.10
25% 25%
59%
EBIT (Operating Income) EBIT -13 -13
40% 40%
-7,627%
Net Profit -13 -13
61% 61%
-7,571%

In millions USD.

Don't miss a Thing! We will send you all news about Alterity Therapeutics Ltd. Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alterity Therapeutics Ltd. Sponsored ADR Stock News

Neutral
GlobeNewsWire
29 days ago
Highlights Granted U.S. FDA Fast Track Designation for ATH434 to treat Multiple System Atrophy (MSA) Reported positive topline data from open-label Phase 2 clinical trial of ATH434 in MSA Presented additional analyses from the ATH434-201 trial demonstrating continued robust efficacy for the treatment of MSA Cash balance on 30 June 2025 of A$40.66M MELBOURNE, Australia and SAN FRANCISCO, July 30...
Neutral
GlobeNewsWire
about one month ago
– ATH434 Demonstrated Clinical Benefit on the Unified MSA Rating Scale and Global Measures of Neurological Symptoms –
Neutral
GlobeNewsWire
about one month ago
– Peer-reviewed publication in Annals of Clinical and Translational Neurology highlights the use of the MSA Atrophy Index developed to diagnose and track disease progression in Multiple System Atrophy –
More Alterity Therapeutics Ltd. Sponsored ADR News

Company Profile

Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

Head office Australia
CEO Dr. Stamler
Employees 10
Founded 1997
Website alteritytherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today